Navigation Links
Pharmaxis Announces NDA Filing for Aridol(TM) (Mannitol Bronchial Challenge Test)
Date:3/3/2009

A Potential New Tool in the Diagnosis and Assessment of Asthma

EXTON, Pa., March 3 /PRNewswire/ -- Pharmaxis, Inc., a wholly owned subsidiary of Pharmaxis Ltd (ASX: PXS, Nasdaq: PXSL), an emerging respiratory specialty pharmaceutical company, announced today that it has filed a New Drug Application (NDA), electronically, with the U.S. Food and Drug Administration (FDA) for Aridol(TM) (mannitol bronchial challenge test). Bronchial challenge tests are designed to assess bronchial hyperresponsiveness, an important marker in the diagnosis and assessment of asthma.

"A definitive asthma diagnosis and effective monitoring and management of the disease have been long-standing challenges for doctors and patients with asthma," said William Storms, MD, Allergist, Colorado Springs, CO. "The primary method of diagnosis -- a detailed history and physical examination of the patient, has remained relatively unchanged for many years and is largely absent of any routine test to confirm the diagnosis."

Brett Charlton MBBS, PhD, Medical Director, Pharmaxis Ltd, added, "Aridol is designed to measure bronchial hyperresponsiveness that corresponds with airway inflammation, an important underlying component of asthma."

Aridol will be a standardized test kit containing proprietary dry-powder mannitol (a naturally occurring sugar alcohol), prepared for delivery to the lungs using a proprietary hand-held inhaler. The goal of Aridol is to provide physicians and health care professionals with an objective measure of active airway inflammation through an easy-to-use, single-use test for asthma care and assessment in a variety of healthcare settings.

"Upon approval healthcare professionals will have an easy-to-administer bronchial challenge test improving their ability to diagnose and assess patients with asthma," said Stephen Beckman, President, Pharmaxis, Inc.

Aridol is approved for sale in Australia, major European countries and Korea. It is the first and only bronchial challenge test approved Europe-wide. Aridol has been included in various asthma, sport and occupational screening guidelines including; the GINA Report of Global Strategy for Asthma Management and Prevention, the U.S. Asthma Management Guidelines, the International Olympic Committee independent medical commission's guidelines for beta-2 agonist use in the 2008 Summer Olympics in Beijing, China, guidelines from the World Anti-Doping Agency, and those issued by other sports-governing bodies to ensure appropriate assessment and management of elite athletes who are asthmatic.

About Pharmaxis

Pharmaxis is an emerging respiratory specialty pharmaceutical company that researches, develops and commercializes new therapies for undertreated respiratory diseases. Its development pipeline includes: Aridol(TM) (mannitol bronchial challenge test) a tool to diagnose and assess asthma; Bronchitol(TM) (mannitol) for Cystic Fibrosis, bronchiectasis, and chronic obstructive pulmonary disease (COPD); PXS25 for the treatment of lung fibrosis; and PXS4159 for asthma. Founded in 1998, Pharmaxis Ltd is headquartered in Frenchs Forest, Australia with U.S. headquarters in Exton, PA. For more information, visit www.pharmaxis.com.


'/>"/>
SOURCE Pharmaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmaxis to Expand Manufacturing Capacity
2. FamilyLink.com, Inc. Announces New Lead Developer
3. Providence Service Corporation Announces That Avalon Correctional Services Has Abandoned Its Consent Solicitation
4. American Psychiatric Foundation Announces Recipients of Helping Hands Grants
5. Acuo Technologies(R) Announces Another Record Sales and Implementation Growth
6. CorNova Announces Addition of Andrew T. Jay, D.M.D., M.B.A., to its Board of Directors
7. Marketing Technology Solutions Announces Strong 2008 Growth and Web Site Enhancements for QualityHealth.com
8. Genoptix Announces Participation at Barclays Capital Global Healthcare Conference
9. Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
10. Osteotech Announces Fourth Quarter and Full Year 2008 Earnings Release and Conference Call; Company to Release Financial Results on Wednesday, March 4, 2009 and Host Call on Thursday, March 5, 2009
11. WellPoint Announces Appearances at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, ... the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where ... city’s history as home to some of the world’s leading providers of cereal and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... The vast majority of dialysis patients currently ... are usually 3 times a week, with treatment times ... time, equipment preparation and wait time.  This regimen can ... patients who are elderly and frail.  Many elderly dialysis ... centers for some duration of time. Residents ...
Breaking Medicine Technology: